XYLOCAINE TOPICAL 4% SPRAY

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

LIDOCAINE HYDROCHLORIDE

Prieinama:

ASTRAZENECA CANADA INC

ATC kodas:

N01BB02

INN (Tarptautinis Pavadinimas):

LIDOCAINE

Dozė:

40MG

Vaisto forma:

SPRAY

Sudėtis:

LIDOCAINE HYDROCHLORIDE 40MG

Vartojimo būdas:

TOPICAL

Vienetai pakuotėje:

50ML

Recepto tipas:

Ethical

Gydymo sritis:

LOCAL ANESTHETICS

Produkto santrauka:

Active ingredient group (AIG) number: 0101280002; AHFS:

Autorizacija statusas:

CANCELLED POST MARKET

Leidimo data:

2015-04-30

Prekės savybės

COPYRIGHT 1955, 2006 ASTRAZENECA CANADA INC. Page 1 of 17
PRESCRIBING INFORMATION
XYLOCAINE
® TOPICAL 4%
(lidocaine hydrochloride topical solution USP)
40mg/mL
Oral Topical Anesthetic
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
L4Y 1M4
www.astrazeneca.ca
Date of Revision: April 2, 2008
SUBMISSION CONTROL NUMBER: 115630
XYLOCAINE
®
is a trade-mark of the AstraZeneca group of companies
COPYRIGHT 1955, 2006 ASTRAZENECA CANADA INC.
Page 2 of 17
TABLE OF CONTENTS
PRESCRIBING INFORMATION
...........................................................................................1
TABLE OF CONTENTS
.........................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................3
SUMMARY PRODUCT
INFORMATION......................................................................3
INDICATIONS AND CLINICAL USE
...........................................................................3
CONTRAINDICATIONS.................................................................................................4
WARNINGS AND PRECAUTIONS
...............................................................................4
ADVERSE REACTIONS
.................................................................................................7
DRUG
INTERACTIONS..................................................................................................8
DOSAGE AND ADMINISTRATION
...........................................................................10
OVERDOSAGE..............................................................................................................11
ACTION AND CLINICAL
PHARMACOLOGY..........................................................13
STORAGE AND STABILITY
.......................................................................................14
DOSAGE FORMS, COMPOSITION AND
PACKAGING...........................................14
PART III: CONSUMER
INFORMATION.............